S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
MU   39.89 (-5.16%)
GE   7.04 (-11.34%)
TSLA   481.56 (-8.10%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
GILD   72.51 (-3.01%)
PRI   84.16 (-4.88%)
DIS   94.92 (-1.74%)
S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
MU   39.89 (-5.16%)
GE   7.04 (-11.34%)
TSLA   481.56 (-8.10%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
GILD   72.51 (-3.01%)
PRI   84.16 (-4.88%)
DIS   94.92 (-1.74%)
S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
MU   39.89 (-5.16%)
GE   7.04 (-11.34%)
TSLA   481.56 (-8.10%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
GILD   72.51 (-3.01%)
PRI   84.16 (-4.88%)
DIS   94.92 (-1.74%)
S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
MU   39.89 (-5.16%)
GE   7.04 (-11.34%)
TSLA   481.56 (-8.10%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
GILD   72.51 (-3.01%)
PRI   84.16 (-4.88%)
DIS   94.92 (-1.74%)
Log in

NASDAQ:JYNT - Joint Stock Price, Forecast & News

$9.59
-1.26 (-11.61 %)
(As of 04/1/2020 04:00 PM ET)
Today's Range
$9.54
Now: $9.59
$10.82
50-Day Range
$8.14
MA: $13.62
$17.10
52-Week Range
$7.67
Now: $9.59
$21.80
Volume343,300 shs
Average Volume146,311 shs
Market Capitalization$133.14 million
P/E Ratio41.70
Dividend YieldN/A
Beta0.9
The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of March 07, 2019, the company operated 450 clinics in the United States. The company was founded in 2010 and is headquartered in Scottsdale, Arizona.
Read More
Joint logo

Industry, Sector and Symbol

Industry Patent owners & lessors
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:JYNT
CUSIPN/A
Phone480-245-5960

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$48.45 million
Cash Flow$0.34 per share
Book Value$0.41 per share

Profitability

Net Income$3.32 million

Miscellaneous

Employees138
Market Cap$133.14 million
Next Earnings Date5/14/2020 (Estimated)
OptionableNot Optionable

Receive JYNT News and Ratings via Email

Sign-up to receive the latest news and ratings for JYNT and its competitors with MarketBeat's FREE daily newsletter.


Joint (NASDAQ:JYNT) Frequently Asked Questions

How has Joint's stock been impacted by COVID-19 (Coronavirus)?

Joint's stock was trading at $13.61 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, JYNT shares have decreased by 29.5% and is now trading at $9.59. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Joint?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Joint in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Joint.

When is Joint's next earnings date?

Joint is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Joint.

How were Joint's earnings last quarter?

Joint Corp (NASDAQ:JYNT) released its quarterly earnings results on Thursday, March, 5th. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.02. The business earned $13.88 million during the quarter, compared to the consensus estimate of $13.33 million. Joint had a net margin of 6.86% and a return on equity of 92.78%. View Joint's earnings history.

What guidance has Joint issued on next quarter's earnings?

Joint updated its FY 2020 After-Hours earnings guidance on Thursday, March, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $61-63 million, compared to the consensus revenue estimate of $61.6 million.

What price target have analysts set for JYNT?

5 brokers have issued 12 month target prices for Joint's stock. Their forecasts range from $20.00 to $32.00. On average, they expect Joint's share price to reach $26.00 in the next twelve months. This suggests a possible upside of 171.1% from the stock's current price. View analysts' price targets for Joint.

What are Wall Street analysts saying about Joint stock?

Here are some recent quotes from research analysts about Joint stock:
  • 1. According to Zacks Investment Research, "The Joint Corp. is a healthcare franchisor of chiropractic clinics. The Company's plans include: Single Visit, Premium Wellness Plan and Wellness Plan. It also provides a family wellness plan. The Company also provides removal of subluxations. It operates its clinics across: Albany, New York; Austin, Texas; Brentwood, California; Fort Mill, South Carolina; Lubbock, Texas; Lynnwood, Washington; Middletown, New Jersey; San Antonio, Texas; San Diego, California and Spartanburg, South Carolina, among others. The Joint Corp. is headquartered in Scottsdale, Arizona. " (3/27/2020)
  • 2. Maxim Group analysts commented, "Market close, JYNT reported relatively inline 2Q19 revenue results and reiterated 2019 guidance. The company opened 14 franchise clinics in 2Q19 versus our estimate of 17, for a total of 417 franchises. JYNT also opened one greenfield clinic bringing that total up to 51. We are increasing our 2020 revenue estimate as we expect the company to continue to open franchise and greenfield clinics while expanding its national footprint. Also, we are introducing our 2020 quarterly estimates." (8/9/2019)

Has Joint been receiving favorable news coverage?

News articles about JYNT stock have trended neutral this week, according to InfoTrie. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Joint earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutJoint.

Are investors shorting Joint?

Joint saw a increase in short interest in March. As of March 13th, there was short interest totaling 2,118,100 shares, an increase of 15.1% from the February 27th total of 1,840,000 shares. Based on an average daily volume of 167,100 shares, the short-interest ratio is currently 12.7 days. Approximately 16.3% of the shares of the stock are short sold. View Joint's Current Options Chain.

Who are some of Joint's key competitors?

What other stocks do shareholders of Joint own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Joint investors own include Advanced Micro Devices (AMD), Catalyst Pharmaceuticals (CPRX), Starbucks (SBUX), Adobe (ADBE), Etsy (ETSY), Okta (OKTA), Aurora Cannabis (ACB), salesforce.com (CRM), Walt Disney (DIS) and NovaBay Pharmaceuticals (NBY).

Who are Joint's key executives?

Joint's management team includes the following people:
  • Mr. Peter D. Holt, CEO, Pres & Director (Age 60)
  • Jake Singleton, Chief Financial Officer (Age 37)
  • Mr. Jorge Armenteros, VP of Operations
  • Dr. James Edwards, Chief Chiropractic & Compliance Officer
  • Mr. Craig P. Colmar, Sec. (Age 66)

When did Joint IPO?

(JYNT) raised $20 million in an initial public offering on Tuesday, November 11th 2014. The company issued 3,000,000 shares at $6.50 per share. Roth Capital Partners and Feltl and Company acted as the underwriters for the IPO and Sanders Morris Harris was co-manager.

What is Joint's stock symbol?

Joint trades on the NASDAQ under the ticker symbol "JYNT."

How do I buy shares of Joint?

Shares of JYNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Joint's stock price today?

One share of JYNT stock can currently be purchased for approximately $9.59.

How big of a company is Joint?

Joint has a market capitalization of $133.14 million and generates $48.45 million in revenue each year. The company earns $3.32 million in net income (profit) each year or $0.23 on an earnings per share basis. Joint employs 138 workers across the globe. View additional information about Joint.

What is Joint's official website?

The official website for Joint is http://www.thejoint.com/.

How can I contact Joint?

Joint's mailing address is 16767 N PERIMETER DRIVE SUITE 240, SCOTTSDALE AZ, 85260. The company can be reached via phone at 480-245-5960 or via email at [email protected]


MarketBeat Community Rating for Joint (NASDAQ JYNT)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  233 (Vote Outperform)
Underperform Votes:  235 (Vote Underperform)
Total Votes:  468
MarketBeat's community ratings are surveys of what our community members think about Joint and other stocks. Vote "Outperform" if you believe JYNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JYNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel